Tech Meridian ← ENTITY INDEX
PROMY MERIDIAN RU

COMPANY · ENTITY #6174

Model Hardware Standard

Related event timeline, sources and context from the news index.

EVENT TIMELINE

3

COMPANIES · 3 SOURCES · TechCrunch AI · The Verge AI · The Decoder

Anthropic launches Claude Meetings, Whiteboards and Sheets to bring Claude into live workplace workflows

Anthropic introduced Claude Meetings — an AI that can join video calls (initially on Google Meet) as a visible participant to follow discussions and draft plans, notes, timelines and action items in real time — plus collaborative Claude Whiteboards and Claude Sheets for shared visual workspaces and spreadsheets. Claude Sheets and Whiteboards are available in beta on paid Team and Enterprise plans; Claude Data (formerly Claude Dashboards) is now generally available, and new interactive connectors let teams open apps like Adobe, Atlassian and HubSpot inside Claude.

7.0

RESEARCH · 1 SOURCE · The Decoder

Claude Sonnet 5 agent autonomously selected and delivered gene therapy in a mouse

Researchers at Exin Therapeutics used Anthropic’s Claude Sonnet 5 to analyze a mouse epilepsy model, choose a gene therapy, pick a brain target and stereotactic coordinates, and control a motorized surgical rig to inject the treatment; a licensed veterinarian approved each irreversible step and the mouse reportedly recovered. Mid-procedure the agent refused to continue after detecting a calibration error, and more capable Claude models (Opus 5/5.5) had earlier declined to perform the live procedure; the work is described in an X thread and a technical report is expected but not yet peer-reviewed.

8.0

COMPANIES · 1 SOURCE · The Decoder

Anthropic building San Francisco-area biology lab where Claude will guide robots

Anthropic is establishing a biology lab near San Francisco to run physical drug experiments with AI guidance; the company plans for Claude to direct robots through experiments using tools such as Claude Science and the Model Hardware Standard, with human oversight retained. The move follows Anthropic's acquisition of Coefficient Bio (about $400 million) and addition of Novartis CEO Vas Narasimhan to its board; Anthropic says it will not run clinical trials for now.

7.0